Kornimate/medical-research-clean huggingface dataset:
cut-off progesterone values deleterious for in vitro fertilization and fresh embryo transfer

Conditions: Progesterone; Fertilization in Vitro; Infertility; Pregnancy

Summary: at which deleterious cut off value of progesterone on day of hcg (p-hcg) in our ivf program should fresh embryo transfer (et) be cancelled?

there is still an ongoing debate on the effect of subtle increased p-hcg concentration on pregnancy outcome after fresh et. no consensus on the cut-off value to define increased p-hcg seems to exist. it is accepted that high p advances endometrium, leading to asynchrony between the implanting embryo and the endometrium, and resulting in implantation failure. a freeze all embryos policy and postponement of et in subsequent frozen-thawed cycle has been proposed.

Eligibility criteria:
inclusion criteria: * fresh embryo transfer * progesterone value on day hcg (human choriogonadotrophin hormone) exclusion criteria: * clinical indication for delaying embryo transfer
analysis of cmtm6 expression in patients with acute myeloid leukemia

Conditions: Acute Myeloid Leukemia, Adult

Summary: in this study, we aim to investigate the expression of cklf like marvel transmembrane domain containing 6 (cmtm6) in leukemia cells of patients with acute myeloid leukemia (aml). we will use peripheral blood samples and assess cmtm6 expression by flow cytometry and western blot.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * primary diagnosis of acute myeloid leukemia * diagnosis results available * written informed consent * ability to understand the nature of the study and the study related procedures and to comply with them exclusion criteria: * age \< 18 years * lack of informed consent
vaccine immunity and inflammation in the aging person living with hiv

Conditions: HIV Infections; Age

Summary: this study will track immune responsiveness to conjugate pneumococcal vaccines over time to help determine how long protection from this vaccine lasts in individuals with chronic medical conditions (in this study - hiv) and with age.

persons living with hiv (plwh) are at increased risk of chronic inflammation and the associated adverse health outcomes. there is considerable evidence that chronic inflammatory conditions like metabolic disease and autoimmune disorders as associated with weakened vaccine responses and existing vaccine studies in plwh do not adequately sample older individuals who are disproportionately affected by this "inflammaging." we hypothesize the effect of age on poor vaccine responses is greater among plwh given the additional burdens of hiv driven inflammation. the overall project goal is to examine this premise by measuring the impact of hiv status, age, and chronic immune activation on conjugate pneumococcal vaccine responses. we will study acute (30 day) and longer-term (2 year) immune responses following pcv vaccination, among a cohort of participants including 4 groups: a) older plwh, age ≥50 (n=100), b) older hiv uninfected controls, age ≥50 (n=50), c) younger plwh, age \<50 (n=50), d) younger hiv uninfected controls, age \<50 (n=50). with these cohorts, we will 1) comprehensively characterize the impact of hiv and age on the immunogenicity of conjugate pneumococcal vaccination by longitudinally tracking adaptive vaccine-specific antibody, b cell and cluster of differentiation 4 t cell responses. we will compare these responses by age and hiv status. we will also 2) determine the influence of chronic inflammation on vaccine-specific immunity among plwh across the adult lifespan by measuring the associate between vaccine immunity and biomarkers of chronic inflammation. this project will provide valuable knowledge on how hiv and age influence vaccine immune responses with the hope of informing vaccine development and schedule to optimize the long-term health of persons living with hiv.

Eligibility criteria:
inclusion criteria: * age\>=18 years * hiv diagnosis * on antiretroviral therapy with hiv viral load\<200 within last year exclusion criteria: * other significant immunosuppressing condition * age\< 18 years * pregnancy (at enrollment) * contraindication to pneumococcal vaccination * known contraindication to non-clinical blood draws (severe anemia last hemoglobin \<8g/dl) * subjects who, in the opinion of the investigator, may be non-adherent to study schedules or procedures. * adults unable to consent * individuals with impaired ability to consent * incarceration at time of enrollment controls inclusion criteria: * age\>=18 years * hiv ag-ab test negative
examining the long-term risks of oophorectomy

Conditions: Coronary Heart Disease; Stroke; Breast Cancer; Ovarian Cancer; Cancer; Hip Fracture; Death

Summary: at the time of hysterectomy for benign disease, the overall health benefits of preserving ovarian function in a large population of women have not been established.

we are conducting a prospective, observational study of 32,175 women participants of the nurse's health study who had a hysterectomy with or without removal of both ovaries. we are evaluating mortality and morbidity due to the following conditions: coronary heart disease, stroke, breast cancer, ovarian cancer, other cancer, hip fracture and death from all causes.

Eligibility criteria:
inclusion criteria: * women who had hysterectomies were classified into simple hysterectomy or hysterectomy with both ovaries removed. exclusion criteria: * evidence of cancer, coronary heart disease (mi or angina pectoris), stroke, or hip fracture before entering the study were excluded. cancer as an indication for hysterectomy also excluded. * women reporting unilateral oophorectomy, unknown oophorectomy status, unknown age of hysterectomy, or those who had oophorectomy before hysterectomy were excluded.

Keywords: oophorectomy ovarian conservation stroke breast cancer ovarian cancer other cancer hip fracture
psoriasis longitudinal assessment and registry

Conditions: Psoriasis

Summary: the purpose of this study is to further evaluate the safety of infliximab, ustekinumab, and guselkumab in patients with plaque and other forms of psoriasis. the study also includes patients receiving other therapies, such as non-biologic and other biologic agents. the registry also evaluates patient and disease characteristics, including patient-reported assessment of psoriatic arthritis (psa); and clinical and quality of life outcomes.

psolar is an ongoing voluntary observational study in which infliximab-exposed patients, ustekinumab-exposed patients, and patients treated with other biologic and non-biologic standard of care therapies have been enrolled internationally and are followed for up to 8 years. additionally, enrollment is opened to include at least 2000 guselkumab-exposed patients and up to 2000 patients exposed to il-17 inhibitors. the registry does not require any study-specific testing, but may capture information collected as part of normal routine care. patient information is collected at the enrollment visit and about every 6 months thereafter. at enrollment, information on demographics (e.g. gender, and race), medical history and family medical history, details of past and current psoriasis treatments, and current psoriasis medications is collected. at enrollment and each follow-up visit, data are collected regarding physical examination, clinical disease status, quality of life assessments, current psoriasis medications, patient-reported psa assessments, and adverse events. no study agents are administered for the purpose of this registry; all patients receive standard of care treatment as prescribed by the patient's physician.

Eligibility criteria:
inclusion criteria: * have a diagnosis of psoriasis * incident or prevalent users of tremfya or an il-17 inhibitor (eg, secukinumab, ixekizumab, brodalumab, bimekizumab) at the time of their enrollment. incident users are defined as those participants starting treatment within 30 days before or after the enrollment visit and prevalent users are defined as those who are on treatment greater than 30 days prior to the enrollment visit * ability to understand and sign an informed consent form * are willing to participate in regular follow-up visits exclusion criteria: * refuse to consent or are unwilling to respond to requests for long term information within the required time frame * are participating or have already planned to participate in a clinical trial with non-marketed investigational agents or are participating in a janssen-sponsored clinical trial with marketed agents

Keywords: psoriasis psoriatic arthritis skin disease infliximab ustekinumab guselkumab etanercept adalimumab secukinumab ixekizumab brodalumab systemic therapy observational registry
effect of statin treatment on insulin sensitivity during myocardial infarction

Conditions: Myocardial Infarction

Summary: stress hyperglycemia during myocardial infarction (mi) is related to mortality at short and long term. recent studies, however, revealed that chronic statin treatment may decrease both insulin sensitivity and secretion immediately after statin therapy initiation. this study aim was to investigate the dose-dependent effect of statins on insulin sensitivity in patients in the acute phase of mi.

stress hyperglycemia during myocardial infarction (mi) is a predictor of worse prognosis at short and long term. from the mechanistic standpoint, hyperglycemia can attenuate thrombolysis, increase platelet aggregation, induce coronary vasoconstriction, reduce oxygen transport and prolong endothelial inflammation after mi. consistently, observational data indicates that glucose normalization improves survival in hyperglycemic patients hospitalized with mi. high dose potent statins have been included in the early treatment of acute coronary syndromes (acs) based upon a broad range of potentially beneficial mechanisms. recent studies, however, revealed that chronic statin treatment may increase the incidence of type 2 diabetes mellitus in a dose-dependent manner. moreover, according to studies in cellular and animal models, such decrease in insulin sensitivity may be observed immediately after statin therapy initiation. by inference, one may speculate that statin treatment initiated at the acute phase of mi may potentially favor the appearance or aggravation of stress hyperglycemia. to date, however, this hypothesis has not been investigated. hence, this study aim was to investigate the dose-dependent effect of statins on insulin sensitivity in patients in the acute phase of mi.

Eligibility criteria:
inclusion criteria: * less than 24 hours after the onset of mi symptoms * st-segment elevation of a least 1 mm (frontal plane) or 2 mm (horizontal plane) in two contiguous leads * myocardial necrosis, as evidenced by increased creatine kinase-mb (ck-mb) and troponin levels exclusion criteria: * diabetes or prior use of statins in the last 6 months

Keywords: statin myocardial infarction insulin sensitivity
a prospective cohort study of 68ga-fapi-pet-ct versus fdg-pet-ct for ovarian cancer

Conditions: Ovarian Cancer

Summary: a study to discuss the advantage of fapi pet- ct in the initial diagnosis staging and lesion determination of ovarian cancer,whether it can be a evaluation strategy as an r0 evaluation tool or a prediction tool of chemotherapy response and evaluation of prognosis.

ovarian cancer is a challenging disease. it is difficult to diagnose early, and the recurrence rate is high after initial treatment. in the past decades, in addition to cancer treatment methods, imaging evaluation has also made corresponding progress. in particular, molecular imaging using fdg-pet / ct has shown a strong role in ovarian cancer. it can locate metabolic changes before anatomical changes, point out small lymph node (ln) metastasis, find distant metastasis and definite recurrence.in terms of diagnosis, several studies have shown that pet-ct is superior to ct in ovarian cancer staging and has obvious advantages in the determination of extraperitoneal metastasis; in terms of predicting whether ro surgery can be performed, there are some mature scoring systems, such as eisenkop,suidan score etc.but there is still no unique scoring mode suitable for pet-ct; despite the above advantages, the nonspecific uptake mechanism of fdg-pet may lead to false positive results.cancer associated fibroblasts (cafs) are one of the factors that independently mediate tumor growth and metastasis. they are also related to extracellular fibrous tissue and tumor size fibroblast activation protein (fap) is overexpressed in fibroblasts of many epithelial cancers, but rarely expressed in normal tissues.therefore, imaging with fap as a marker is a promising way in many tumor types in our previous study, \[68ga\] ga dotafapi - pet / ct d compared with \[18f\] - fdg pet / ct has advantages in detecting primary and metastatic lesions of many tumors, especially peritoneal metastatic tumors, such as ovarian cancer.

Eligibility criteria:
inclusion criteria: 1. patients with primary epithelial ovarian cancer confirmed by clinical consideration or puncture 2. pet-ct was chose as the initial imaging evaluation tool. exclusion criteria: 1. patients with acute inflammation 2. lacking of clinical data 3. severe complications and pet-ct contraindications

Keywords: ovarian cancer fapi pet-ct
effect of canagliflozin on ultrafiltration & fibrosis in patients on peritoneal dialysis

Conditions: ESRD; CKD (Chronic Kidney Disease) Stage 5D

Summary: this is a phase ii, proof-of-concept, placebo-controlled, double-blind, cross-over randomized clinical trial, assessing the effect of canagliflozin on peritoneal membrane function in patients on pd. the primary aim of this trial is to determine the short-term effects of canagliflozin, an sglt-2 inhibitor, on glucose absorption by the peritoneal membrane and on ultrafiltration, as assessed by a standardized peritoneal equilibrium test. the secondary aims are to determine the effect of canagliflozin on solute clearance and on effluent biomarkers of inflammation, angiogenesis, and fibrosis at 26 weeks. we hypothesize that canagliflozin will prevent glucose absorption by the peritoneal membrane, as compared with placebo, and will attenuate the development of inflammation, angiogenesis, and fibrosis of the peritoneal membrane, as assessed by relevant biomarkers in the dialysate.

patients with kidney failure on peritoneal dialysis who meet the study inclusion criteria will be randomized at a 2:2:1 ratio to one of the following arms: (i) canagliflozin 300 mg once daily for 5 weeks (double-blind), followed by matching placebo once daily for 5 weeks (double-blind), followed by canagliflozin 300 mg once daily for 16 weeks (open label). (ii) placebo once daily for 5 weeks (double-blind), followed by canagliflozin 300 mg once daily for 5 weeks (double-blind), followed by canagliflozin 300 mg once daily for 16 weeks (open label). (iii) standard of care, with no active treatment, for 26 weeks (open label). four in-person and one phone study visits have been scheduled: baseline visit, week 5, week 10, week 18 (phone visit), and week 26. a standardized peritoneal equilibration test (pet) will be performed at each of the in-person visits. there will also be two safety assessments at weeks 2 and 7, which will consist of blood tests. patients who develop intercurrent illnesses or are hospitalized may temporarily discontinue the study drug if deemed appropriate by the treating physician.

Eligibility criteria:
inclusion criteria: * adult patients with kidney failure on pd (both incident and prevalent) who are on a stable prescription of dextrose-based solutions for at least 3 months. * only high or high-average transporters, as classified by pet, will be included. exclusion criteria: * history of euglycemic ketoacidosis * known hypersensitivity to canagliflozin * active peritonitis or tunnel infection * kidney transplant scheduled in the next 6 months * severe liver cirrhosis (child-pugh class c stage) * recurrent severe genital or urine infections * patients receiving digoxin, phenobarbital, phenytoin, rifampin, or ritonavir if these agents cannot be safely discontinued * pregnancy or breastfeeding

Keywords: sglt-2 inhibitors canagliflozin ultrafiltration failure peritoneal fibrosis peritoneal dialysis
impact of different electric pumping modalities on milk volume production in mothers of preterm infants

Conditions: Prematurity

Summary: initiating and sustaining breastfeeding are common challenges in neonatal units. it is known that hindmilk expressed at the end of the expression session has a higher fat content. previous studies have shown that simultaneous pumping is more effective at producing milk than sequential pumping. however this approach is often felt uncomfortable by the mothers, and sequential pumping is preferred. the purpose of this study is to determine which modality of milk expression by electric pump is the most efficient and productive when sequential pumping is used.this is done by assessing the milk volume expressed per expression and its macronutrients content.

the study will last for 6 days. each mother will express breast milk following two designed modalities in a random fashion, for two days each. the two designed modalities are: 1. complete pumping of one breast (first left) for 15 min, followed by complete pumping of the right breast for 15 min, until the breast is empty. 2. pumping both breast simultaneously for 15 min. at day one of the study, the mothers will follow the standard pumping modality in practice at our department. in between the two studied procedures at day 4 of the study, the mothers will again follow the standard pumping modality. on each day of the study, in the morning after the first expression of the day, a sample of 2 ml of pumped breastmilk will be taken, and the total volume of the daily expressed milk will be recorded.

Eligibility criteria:
inclusion criteria: * mothers of preterms exclusion criteria: * hiv infected mothers

Keywords: mothers of preterms breastfeeding mothers of preterm infants mother milk feeding
time to eat study - pilot

Conditions: Overweight

Summary: the goals of this pilot study is to evaluate the safety and feasibility of time restricted feeding in an older adult population.

for this 4-week pilot study, the study team will recruit 10 overweight, older adults who are at risk for, or have, mobility impairment, as measured by slow gait speed and self-reported mobility difficulty and self-reported sedentary lifestyle. all participants will receive the time restricted feeding intervention, which will consist of limiting the time in which food is consumed to 8 hours per day and fasting for 16 hours per day. the study will also assess the variance of inflammatory markers, walking speed, physical and cognitive function, grip strength, body measurements, perceived fatigability, health related quality of life and activity level. this allows the refinement of the design, recruitment yields, target population, adherence, retention, and tolerability of a larger scale study.

Eligibility criteria:
inclusion criteria: * consent to participate in the study * men and women ≥ 65 years old * self-reported difficulty walking ¼ mile or climbing a flight of stairs * self-reported sedentariness (\<30 minutes structured exercise per week) * walking speed \<1 m/sec on the 4 m walk test * able to walk unassisted (cane allowed) * have a body mass index between 25 - 40 kg/m2 (inclusive) exclusion criteria: * current dietary habits * fasting \>12 hours per day * actively trying to lose weight by participating in formal weight loss program or significantly restricting calorie intake * weight loss \> 5 lbs in the past month * medical history or conditions * resting heart rate of \>120 beats per minute, systolic blood pressure \> 180 mmhg or diastolic blood pressure of \> 100 mmhg * unstable angina, heart attack or stroke in the past 3 months * continuous use of supplemental oxygen to manage a chronic pulmonary condition or heart failure * rheumatoid arthritis, parkinson's disease or currently on dialysis * active treatment for cancer in the past year * insulin dependent diabetes mellitus * taking medications that preclude fasting for 16 hours (e.g. must be taken with food at least 12 hours apart) * any condition that in the opinion of the investigator would impair ability to participate in the trial

Keywords: intermittent fasting inflammation diet lifestyle eating habits time restricted feeding
effectiveness of micro connective tissue graft for treatment of multiple adjacent gingival recession defects

Conditions: Gingival Recession, Localized

Summary: the objective of this project is to evaluate 1-year outcomes of treatment of magrd using a modified coronally advanced tunnel technique (mcat) with either conventional ctg (control group) or micro-ctg (test group).

gingival recession defects (grd) present as a partial exposure of the root surface resulting from gingival margin displacement apical to the cemento-enamel junction (cej). a variety of surgical methods have been reported to reestablish root coverage, including tunneling techniques and coronally and laterally advanced flaps. as the presence of thin gingival tissues is one of the predisposing factors for grd, the adjuvant use of subepithelial connective tissue grafts (ctgs) during the surgical correction is often considered. ctgs are thought to contribute to phenotype modification and stability of treatment outcomes and studies have indicated favorable esthetic results and high degrees of root coverage (documented range: 69% to 97%). the procedure does, however, require a suitable donor site. when multiple adjacent teeth exhibit grds, the preferred surgical approach should offer the greatest possible root coverage, while limiting drawbacks (i.e., patient morbidity, esthetic problems). thus, one of the challenges related to coverage of multiple grds is the scarcity of donor tissue. in cases when large ctgs are required, additional surgical procedures may even be necessary. as an alternative, a modification of the harvested ctg into multiple "micro-ctgs" is proposed for the treatment of multiple adjacent grds (magrd). in the present study, the effectiveness and predictability of micro-ctgs will be evaluated in direct comparison to conventional ctgs. the investigators hypothesise that no statistically significant differences will be observed in terms of % root coverage (primary outcome) and patient satisfaction at 12 months (non-inferiority). the investigators hypothesise that subjects in the test group (micro-ctg) will report significantly lower morbidity at 1 and 2 weeks post-surgery when compared to controls (superiority).

Eligibility criteria:
inclusion criteria: * age ≥18 years, * systemically healthy, * presenting with a minimum of 4 and a maximum of 6 adjacent rt1/rt2 recessions, located in the maxilla or mandible with an apico-coronal extension (i.e. recession depth) of ≥2 mm, * full-mouth plaque score (fmps) \<20%, * full-mouth bleeding score (fmbs) \<20%. exclusion criteria: * pregnancy or lactation, * tobacco smoking, * uncontrolled medical condition, * medication that can affect gingival conditions. * thick phenotype, * severe tooth malpositioning, * uncorrected trauma from toothbrushing, * a previous history of root coverage procedures * the presence of furcation defects.
radiation impact on thromboembolic events

Conditions: Malignant Neoplasm

Summary: the aim of the present study is to determine the frequency and to identify main risk factors for venous thromboembolism of venous thromboembolic complications in a population of cancer patients treated with a curative intent by ionizing radiation.


Eligibility criteria:
inclusion criteria: * patient with a solid cancer (all locations) treated with radiation therapy and / or brachytherapy as curative intent * to be 18 exclusion criteria: * patient with metastatic cancer, * patients whose follow-up at 6 months is not possible * patient receiving an anti-coagulative medication (curative doses) * pregnant or breastfeeding women, * person under protection of justice or unable to give consent

Keywords: radiation therapy thrombosis